Oct-4 +/Tenascin C + neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

Cell Research

Volumn 21, Issue 10, 2011, Pages 1470-1486

  Pezzolo, Annalisa ^a   Parodi, Federica ^a   Marimpietri, Danilo ^a   Raffaghello, Lizzia ^a   Cocco, Claudia ^b   Pistorio, Angela ^c   Mosconi, Manuela ^c   Gambini, Claudio ^c   Cilli, Michele ^d   Deaglio, Silvia ^e   Malavasi, Fabio ^e   Pistoia, Vito ^a  

^a Laboratory of Oncology   (Italy)

^b AIRC Tumor Immunology Unit   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

neuroblastoma; progenitor cells; Tenascin C; tumor derived endothelium; vascular mimicry

Indexed keywords

MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ONCOPROTEIN; POU5F1 PROTEIN, HUMAN; TENASCIN;

ANIMAL; ARTICLE; BONE MARROW; CANCER STEM CELL; CELL DIFFERENTIATION; CHILD; CLINICAL TRIAL; DRUG RESISTANCE; ENDOTHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; INFANT; MALE; METABOLISM; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NUDE MOUSE; PATHOLOGY; PRESCHOOL CHILD; XENOGRAFT;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; ONCOGENE PROTEINS; TENASCIN; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS;

EID: 80053630941     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2011.38     Document Type: Article

References (78)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216. (Pubitemid 37328872)
2. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-414. (Pubitemid 26051001)
3. Dhakal HP, Naume B, Synnestvedt M, et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res 2008;14:2341-2350. (Pubitemid 351551066)
4. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410. (Pubitemid 37328844)
7. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3:411-421. (Pubitemid 37328845)
8. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 2007;25:376-383. (Pubitemid 350002985)
9. Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumor stem/progenitor cells. J Cell Mol Med 2009;13:309-319.
10. Ribatti D, Nico B, Pezzolo A, et al. Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumor-derived interferon-gamma. Br J Cancer 2006;94:1845-1852. (Pubitemid 43882575)
11. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 2008;3:e1652.
12. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-956. (Pubitemid 41345211)
13. Kim JB, Sebastiano V, Wu G, et al. Oct-4 induced pluripotency in adult neural stem cells. Cell 2009;136:411-419.
14. Babaie Y, Herwig R, Greber B, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2007;25:500-510. (Pubitemid 46232806)
15. Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008;3:e2637.
16. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-370. (Pubitemid 37491097)
17. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008;3:e3077.
18. Huang D, Gao Q, Guo L, et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009;18:465-473.
19. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and highgrade oral squamous cell carcinoma. Clin Cancer Res 2008;14:4085-4095.
20. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008;26:1818-1830.
21. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872. (Pubitemid 350138099)
22. Pietras A, Hansford LM, Johnsson AS, et al. HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:16805-16810.
23. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005;37:1066-1083. (Pubitemid 40311747)
24. Hirata E, Arakawa Y, Shirahata M, et al. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci 2009;100:1451-1459.
25. Zagzag D, Friedlander DR, Miller DC, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995;55:907-914.
26. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009;27:1884-1892.
27. Garcion E, Halilagic A, Faissner A, ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 2004;131:3423-3432. (Pubitemid 39139888)
28. von Holst A, Egbers U, Prochiantz A, Faissner A. Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. J Biol Chem 2007;282:9172-9181. (Pubitemid 47093541)
29. von Holst A. Tenascin C in stem cell niches: redundant, permissive or instructive? Cells Tissues Organs 2008;188:170-177. (Pubitemid 351962240)
30. Atlasi Y, Mowla SJ, Ziaee SA, et al. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 2008;26:3068-3074.
31. Wang X, Zhao Y, Xiao Z, et al. Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells 2009;27:1265-1275.
32. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006;6:93-106. (Pubitemid 43361585)
33. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007;133:928-939.
34. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
35. Pietras A, Gisselsson D, Ora I, et al. High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol 2008;214:482-488. (Pubitemid 351340568)
36. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct-4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502. (Pubitemid 40246573)
37. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007;120:1598-1602. (Pubitemid 46355399)
38. Sotomayor P, Godoy A, Smith GJ, Huss WJ. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009;69:401-410.
39. Karoubi G, Cortes-Dericks L, Gugger M, Galetta D, Spaggiari L, Schmid RA. Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma. J Surg Oncol 2010;102:689-698.
40. Covello KL, Kehler J, Yu H, et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006;20:557-570. (Pubitemid 43345322)
41. Miettinen M, Chatten J, Paetau A, Stevenson A. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998;22:327-332. (Pubitemid 28108414)
42. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006;98:1142-1157. (Pubitemid 44288789)
43. Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol 2003;162:1019-1026. (Pubitemid 36237508)
44. Lim SC. CD24 and human carcinoma: tumor biological aspect. Biomed Pharmacother 2005;59:S351-S354.
45. Bunone G, Mariotti A, Compagni A, Moranti E, Della Valle G. Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells. Oncogene 1997;14:1463-1470. (Pubitemid 27182436)
46. Prasannan L, Misek DE, Hinderer R, Michon J, Geiger JD, Hanash SM. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000;6:3949-3956.
47. Uccini S, Mannarino O, McDowell HP, et al. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res 2005;11:380-390.
48. Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 2004;279:27994-27999. (Pubitemid 38900069)
49. Saito M, Yu RK, Cheung NK. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 1985;127:1-7. (Pubitemid 15146924)
50. Wachowiak R, Rawnaq T, Metzger R, et al. Universal expression of cell adhesion molecule NCAM in neuroblastoma in contrast to L1: implications for different roles in tumor biology of neuroblastoma? Pediatr Surg Int 2008;24:1361-1364.
51. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010;29:6115-6124.
52. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumor tissue microarray technique. Histopathology 2007;50:472-483. (Pubitemid 46328190)
53. Bussolati B, Deregibus MC, Camussi G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol 2010;8:220-232.
54. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008;111:4862-4870.
55. Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 2001;31:557-568. (Pubitemid 32835111)
56. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008;22:3696-3705.
57. Alvero AB, Fu HH, Holmberg J, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009;27:2405-2413.
58. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumor vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature 2010;468:824-828.
59. Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010;133:983-995.
60. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010;102:789-795.
61. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-3284.
62. Jung M, Peterson H, Chavez L, et al. A data integration approach to mapping OCT4 gene regulatory networks operative in embryonic stem cells and embryonal carcinoma cells. PLoS One 2010;5:e10709.
63. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-6625. (Pubitemid 37322939)
64. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notchdependent hematopoietic stem cells. Cell Stem Cell 2010;6:251-264.
65. Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007;67:11234-11243. (Pubitemid 350248549)
66. Bozzi F, Collini P, Aiello A, et al. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma. Anticancer Res 2008;28:1565-1569. (Pubitemid 351892930)
67. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007;109:4245-4248. (Pubitemid 46743389)
68. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-7282. (Pubitemid 39382161)
69. Sivasankaran B, Degen M, Ghaffari A, et al. Chiquet-Ehrismann R, Boulay JL. Tenascin-C is a novel RBP Jkappainduced target gene for Notch signaling in gliomas. Cancer Res 2009;69:458-465.
70. Mahller YY, Williams JP, Baird WH, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009;4:e4235.
71. Marzi I, D'Amico M, Biagiotti T, et al. Purging of the neuroblastoma stem cell compartment and tumor regression on exposure to hypoxia or cytotoxic treatment. Cancer Res 2007;6:2402-2407. (Pubitemid 46548922)
72. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477. (Pubitemid 23228250)
73. Malavasi F, Deaglio S, Zaccarello G, et al. The hidden life of NAD+-consuming ectoenzymes in the endocrine system. J Mol Endocrinol 2010;45:183-191.
74. Weidner N. Current pathologic methods for measuring intratumoral micro-vessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-180.
75. Davico Bonino L, De Monte LB, Spagnoli GC, et al. Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma. Int J Cancer 1995;61:509-515.
76. Vescovi AL, Galli R, Reynolds BA. Brain tumor stem cells. Nature Rev 2006;6:425-436.
77. Loriot A, De Plaen E, Boon T, De Smet C. Transient downregulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006;281:10118-10126. (Pubitemid 43864547)
78. Sokal RR, Rohlf FJ. The principle and practice of statistics in biological research. In: Freeman WH, ed. Biometry. New York: Academic Press, 1981:40-58.